Wall Street analysts forecast that Syneos Health Inc (NASDAQ:SYNH) will report earnings per share of $0.70 for the current quarter, according to Zacks Investment Research. Six analysts have made estimates for Syneos Health’s earnings, with the highest EPS estimate coming in at $0.71 and the lowest estimate coming in at $0.68. Syneos Health reported earnings per share of $0.62 in the same quarter last year, which would suggest a positive year-over-year growth rate of 12.9%. The business is scheduled to report its next earnings report before the market opens on Tuesday, August 6th.
On average, analysts expect that Syneos Health will report full-year earnings of $3.12 per share for the current fiscal year, with EPS estimates ranging from $3.07 to $3.14. For the next fiscal year, analysts expect that the company will report earnings of $3.59 per share, with EPS estimates ranging from $3.50 to $3.76. Zacks Investment Research’s earnings per share calculations are an average based on a survey of sell-side research analysts that that provide coverage for Syneos Health.
Syneos Health (NASDAQ:SYNH) last issued its earnings results on Thursday, May 9th. The company reported $0.59 EPS for the quarter, topping the Thomson Reuters’ consensus estimate of $0.51 by $0.08. The business had revenue of $1.12 billion during the quarter, compared to analysts’ expectations of $1.09 billion. Syneos Health had a return on equity of 9.55% and a net margin of 0.42%. Syneos Health’s revenue was up 5.8% compared to the same quarter last year. During the same quarter last year, the firm posted $0.55 earnings per share.
Institutional investors and hedge funds have recently added to or reduced their stakes in the stock. First Trust Advisors LP lifted its stake in Syneos Health by 51.5% in the fourth quarter. First Trust Advisors LP now owns 12,233 shares of the company’s stock worth $481,000 after acquiring an additional 4,160 shares during the period. LPL Financial LLC lifted its stake in Syneos Health by 9.1% in the fourth quarter. LPL Financial LLC now owns 9,762 shares of the company’s stock worth $384,000 after acquiring an additional 812 shares during the period. PNC Financial Services Group Inc. lifted its stake in Syneos Health by 6.4% in the fourth quarter. PNC Financial Services Group Inc. now owns 3,554 shares of the company’s stock worth $141,000 after acquiring an additional 214 shares during the period. Advisor Group Inc. lifted its stake in Syneos Health by 20.6% in the fourth quarter. Advisor Group Inc. now owns 5,231 shares of the company’s stock worth $206,000 after acquiring an additional 895 shares during the period. Finally, Bessemer Group Inc. purchased a new stake in Syneos Health in the fourth quarter worth about $59,000.
Shares of Syneos Health stock traded up $2.92 during midday trading on Tuesday, hitting $52.25. The company’s stock had a trading volume of 379,988 shares, compared to its average volume of 645,179. The stock has a market cap of $5.12 billion, a price-to-earnings ratio of 19.94, a P/E/G ratio of 1.76 and a beta of 1.53. The company’s 50-day simple moving average is $49.14. The company has a debt-to-equity ratio of 1.07, a current ratio of 1.02 and a quick ratio of 1.02. Syneos Health has a 1-year low of $36.26 and a 1-year high of $56.34.
About Syneos Health
Syneos Health, Inc operates as an integrated biopharmaceutical solutions company in North America, Europe, the Middle East, Africa, the Asia-Pacific, and Latin America. It operates through two segments, Clinical Solutions and Commercial Solutions. The Clinical Solutions segment offers various clinical development services spanning Phase I to Phase IV, including full-service global studies, as well as clinical monitoring, investigator recruitment, patient recruitment, data management, and study startup to assist customers with drug development process.
Recommended Story: What is an overbought condition?
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Syneos Health Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Syneos Health and related companies with MarketBeat.com's FREE daily email newsletter.